A new independent study finds Oregon’s licensed service centers screen clients carefully and keep every session supervised. It also finds that most people who could benefit can’t afford to walk through the door.
For three years, Oregon has been running the country’s first regulated psilocybin services program, and for three years supporters and skeptics alike have asked the same question: what actually happens when someone calls a licensed center? We now have the first independent answer, and it’s an encouraging one.
Researchers from Washington University School of Medicine in St. Louis and the University of Missouri published a study on October 12 in Health Affairs Scholar evaluating how Oregon’s licensed psilocybin service centers handle prospective clients in the real world, outside the controlled conditions of a clinical trial. Their verdict: the safety framework Oregon built is working as designed. Their warning: cost is putting that framework out of reach for most of the people it was meant to serve.
How the study worked
The team used a “mystery shopper” design, a long-standing method in health services research. Researchers called centers posing as prospective clients who described depression along with a clinically relevant risk factor, either a personal history of alcohol use disorder or a family history of psychosis. They then recorded whether staff asked the screening questions Oregon’s rules require, including questions about medications, psychiatric history, and suicidal thoughts, and what prices they were quoted.
Of the 22 centers operating at the time, the researchers reached 15.
What they found: a safety system that holds up
The results were remarkably consistent across centers:
- No unsupervised or take-home use. Not one center offered psilocybin to go. Oregon’s model is not functioning like a dispensary.
- Thorough screening, every time. Every center asked about psychiatric history, current medications, and contraindications before discussing next steps.
- Medication interactions flagged. Nearly every center identified psychoactive medications that shouldn’t be combined with psilocybin.
- Medical decisions left to prescribers. No center told a caller on antidepressants to stop their medication without first talking to their doctor, an important safeguard given the risks of abrupt discontinuation.
The researchers noted that the calls were more than box-checking. Facilitators engaged callers in real conversations and worked to understand their history before recommending services. One of the study’s senior authors acknowledged the team had gone in wondering whether centers might hand out psilocybin with little screening, and came away surprised by how detailed the questions were.
These findings add to a recent cohort study of 346 Oregon clients that found serious adverse reactions were uncommon. Together, they form an early but growing body of evidence that Oregon’s regulatory model is protecting the people it serves.
The catch: $1,900 and no insurance
The study’s central concern is affordability. The median price of a supervised session was $1,900, and not one center accepted insurance.
The strain shows up on the provider side, too. Of the 26 centers Oregon had licensed, four had already closed before the study’s calls began, and seven more couldn’t be reached. When researchers followed up with center staff, they heard that high operating and licensing costs make these services hard to sustain for providers and hard to afford for clients.
The study’s lead author put the paradox plainly: Oregon has served more people through a regulated psilocybin model than anywhere else in the world, yet these services remain out of reach for most Americans who are struggling.
That gap matters most for people with the fewest options. The researchers pointed to veterans in particular, some of whom, lacking affordable regulated care at home, are traveling abroad for unregulated treatment instead.
Why this matters beyond Oregon
States across the country are watching Oregon as they weigh their own approaches, and federal policymakers are considering pathways for psychedelic therapies. This study gives all of them something they haven’t had before: real-world evidence that a state-regulated model can deliver careful screening and supervised care.
It also makes clear what the next chapter has to address. A system can be safe and still fail the public if only a few can use it. The task now is to keep the safeguards that are working while building the economic foundation that lets centers stay open and lets clients afford care.
Where NPA stands
The National Psychedelics Association’s work is built around three priorities: access, awareness, and alignment. This study speaks directly to all three.
- Access: Safety without affordability isn’t access. NPA is working with providers, policymakers, and partners on practical solutions, from sustainable operating models for licensed centers to equitable access pathways for veterans and low-income clients.
- Awareness: Independent evidence like this deserves a wide audience. Oregon’s providers are doing careful, responsible work, and the public and lawmakers should know it.
- Alignment: The path forward depends on providers, regulators, researchers, and advocates working from the same facts. This study is a strong shared starting point.
Oregon has shown that regulated psilocybin services can be delivered responsibly. Now we have to make sure they can be delivered to the people who need them.
Source: Adams, D., Cabassa, L.J., Xu, K., et al. Study published October 12, 2026, in Health Affairs Scholar*. Coverage via Bioengineer.org and the Washington University news release.*
Want to support affordable, responsible access to psychedelic-assisted care? DONATE or JOIN
Leave a Reply